Therapeutic effects of lysophosphatidylcholine in experimental sepsis
Author: ["Ji-Jing Yan","Jun-Sub Jung","Jung-Eun Lee","Jongho Lee","Sung-Oh Huh","Hee-Sung Kim","Kyeong Cheon Jung","Jae-Young Cho","Ju-Suk Nam","Hong-Won Suh","Yung-Hi Kim","Dong-Keun Song"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Sepsis represents a major cause of death in intensive care units. Here we show that administration of lysophosphatidylcholine (LPC), an endogenous lysophospholipid, protected mice against lethality after cecal ligation and puncture (CLP) or intraperitoneal injection of Escherichia coli. In vivo treatment with LPC markedly enhanced clearance of intraperitoneal bacteria and blocked CLP-induced deactivation of neutrophils. In vitro, LPC increased bactericidal activity of neutrophils, but not macrophages, by enhancing H2O2 production in neutrophils that ingested E. coli. Incubation with an antibody to the LPC receptor, G2A, inhibited LPC-induced protection from CLP lethality and inhibited the effects of LPC in neutrophils. G2A-specific antibody also blocked the inhibitory effects of LPC on certain actions of lipopolysaccharides (LPS), including lethality and the release of tumor necrosis factor-α (TNF-α) from neutrophils. These results suggest that LPC can effectively prevent and treat sepsis and microbial infections.
Cite this article
Yan, JJ., Jung, JS., Lee, JE. et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10, 161–167 (2004). https://doi.org/10.1038/nm989
